Janux Therapeutics (NASDAQ: JANX)
$41.89
(3.8%)
$1.55
Price as of June 28, 2024, 4:00 p.m. ET
Janux Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Janux Therapeutics Company Info
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.
News & Analysis
Featured Article
Why Janux Therapeutics Stock Is Crushing It This Week
Janux's silence about a potential acquisition deal could be golden.
Keith Speights | Apr 12, 2024
Featured Article
Why Janux Therapeutics Stock Soared as the Market Sagged Today
One of the hotter biotech companies on the scene might be changing owners before long.
Eric Volkman | Apr 10, 2024
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
Alex Carchidi | Mar 2, 2024
The biotech tantalized investors with a very promising data update.
Why Janux Therapeutics Shares Rose 33.1% This Week
Jim Halley | Oct 22, 2022
The clinical-stage biotech company just began its first clinical trial.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.